Alvin Shih
Chief Executive Officer
Biopharmaceutical
Roivant Sciences
Switzerland
Biography
Alvin Shih has served as the Chief Executive Officer of Enzyvant since November 2016. Prior to joining Enzyvant, Dr. Shih was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Before joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Dr. Shih holds an M.D. from the University of Alabama, an M.B.A. from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.
Research Interest
Biotechnology and Internal Medicine
